Background: Close contact between pets and owners provides the opportunity for transmission of antimicrobial resistant organisms like extended-spectrum beta-lactamase (ESBL)/AmpC beta-lactamase (AmpC)-producing Enterobacteriaceae, posing a risk to public health.
Objectives: To investigate whether raw feed is a risk factor for household cats to shed ESBL-producing Enterobacteriaceae, a cohort study was designed. Additionally, raw and non-raw commercial pet food products were screened for the presence of ESBL-producing Enterobacteriaceae.
Methods: Weekly fecal samples of 17 cats in the control group and 19 cats in the exposed group were collected for three weeks and analyzed for the presence of ESBL-producing Enterobacteriaceae. Questionnaires were obtained to determine additional risk factors. Fecal samples were cultured on MacConkey agar supplemented with 1 mg/L cefotaxime. PCR and sequence analysis was used for screening for ESBL genes in suspected isolates. Pet food samples were cultured in LB broth supplemented with 1 mg/L cefotaxime and processed as described above.
Results: In the cohort study, ESBL-producing bacteria were isolated from 3 of 51 (5.9%) samples in the control group compared to 37 of 57 (89.5%) samples in the exposed group. A significant association was found between ESBL shedding and feeding raw pet food products (OR = 31.5). No other risk factors were identified in this study. ESBL-producing Enterobacteriaceae were isolated from 14 of 18 (77.8%) raw pet food products and 0 of 35 non-raw pet food products.
Conclusions: This study shows a strong association between shedding of ESBL-producing bacteria in household cats and feeding raw pet food. Raw pet food was often contaminated with ESBL-producing Enterobacteriaceae.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667807 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187239 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Background: Diet has been associated with memory, emotion/stress regulation, structure and function of the hippocampus and amygdala and attenuation of cognitive aging. There is a well-recognized lack of reliability in self-reported dietary intake and great interest in objective metabolic readout of dietary patterns. In this study we constructed dietary profiles from untargeted metabolomics data using a novel metadata-based source annotation method developed at the Dorrestein Lab, also referred to as "foodomics".
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: Greater adherence to the Mediterranean Diet (MeDi) is associated with lower risk for cardiovascular disease, slower cognitive decline, and reduced risk for Alzheimer's Disease (AD). However, its association with AD biomarkers is not well known. We hypothesized that greater MeDi adherence is associated with reduced amyloid and tau PET burden in a community-based sample of older adults in Northern Manhattan.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
The Charles F. and Joanne Knight Alzheimer Disease Research Center, St. Louis, MO, USA.
Background: Calculating an individual's risk for preclinical and symptomatic Alzheimer disease (AD) involves considering their experiences across the lifespan. This includes assessment of childhood experiences as risk factors for dementing disorders in later life.
Method: The Knight Alzheimer Disease Research Center (ADRC) examined the relationship of well-established AD biomarkers with childhood experiences as reported by research participants.
Background: Higher Mediterranean- DASH for Neurodegenerative Delay (MIND) diet scores have previously been associated with larger total brain volume (TBV) in the Framingham Offspring Study (FOS) community-based cohort. We investigated cross-sectional relationships between the MIND diet and structural brain imaging volumes and white matter hyperintensity volume (WMHV) across six community-based cohorts.
Method: We analyzed data from 3130 dementia-, stroke- and other neurological disease free adults (aged 65 to 74) who participated in the Atherosclerosis Risk in Communities (ARIC) cohort, Cardiovascular Health Study (CHS), Three City (3C) cohort, FOS cohort, Rotterdam Study (RS) or the Study of Health in Pomerania (SHIP) cohort.
Background: AL002 is a humanized, TREM2-selective, agonistic IgG1 monoclonal antibody. The INVOKE-2 study is the first to test the efficacy and safety of a TREM2 agonistic antibody in participants with Alzheimer's Disease (AD). A Phase 1 study of AL002 demonstrated dose-dependent target engagement and dose-dependent effects on microglial signaling biomarkers; AL002 was well tolerated at all doses tested.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!